Literature DB >> 27759810

Disability and progression in Afro-descendant patients with multiple sclerosis.

Juliana Calvet Kallenbach Aurenção1, Claudia Cristina Ferreira Vasconcelos1, Luiz Claudio Santos Thuler1,2, Regina Maria Papais Alvarenga1,3.   

Abstract

Multiple sclerosis (MS) prevalence is higher in Caucasian (CA) populations, narrowing the analysis of the impact of Afro-descendant (AD) populations in disease outcomes. Even so, recent studies observed that AD patients have a more severe course. The main objective of this study is to confirm and discuss, through a systematic review, that being AD is a risk factor for disability accumulation and/or severe progression in patients with MS. A systematic review of published data in the last eleven years was performed, which evaluated clinical aspects and long term disability in patients with MS. Fourteen studies were included. Of these fourteen articles, thirteen observed a relationship between ancestry and poorer outcome of MS. African ancestry is a condition inherent in the patient and should be considered as an initial clinical characteristic affecting prognosis, and influencing which therapeutic decision to make in initial phases.

Entities:  

Mesh:

Year:  2016        PMID: 27759810     DOI: 10.1590/0004-282X20160118

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity.

Authors:  Ilya Kister; Tamar Bacon; Gary R Cutter
Journal:  Neurol Clin Pract       Date:  2021-08

2.  Experiences of African American Women with Multiple Sclerosis.

Authors:  Alexa Stuifbergen; Heather Becker; Carolyn Phillips; Shalonda Horton; Janet Morrison; Francisco Perez
Journal:  Int J MS Care       Date:  2020-04-16

Review 3.  How Does the Immune System Enter the Brain?

Authors:  Josephine A Mapunda; Houyam Tibar; Wafa Regragui; Britta Engelhardt
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.